SCHEMBL5845387

SCHEMBL5845387

CN1CCCC1CC(N)c1nc(C2(c3ccc(Cl)cc3)CCCCC2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.48
SLC6A4 P31645 5/20 0.34
SLC6A3 Q01959 5/20 0.34
CHRNB2 P17787 2/20 0.34
CHRNA7 P36544 2/20 0.34
CHRNA5 P30532 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHRNB4 P30926 2/20 0.33
CHRNA3 P32297 2/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB3 Q05901 1/20 0.33
KCNH2 Q12809 3/20 0.33
ADRA1A P35348 3/20 0.32
HRH1 P35367 3/20 0.32
HSD11B1 P28845 2/20 0.32
HRH3 Q9Y5N1 2/20 0.32
SLC22A1 O15245 1/20 0.32
MLNR O43193 1/20 0.32
NR1I2 O75469 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5845392 0.77 BACE1 (0.46) BACE1SLC6A4SLC6A3CHRNB2CHRNA7
SCHEMBL5845190 0.74 BACE1 (0.44) BACE1SLC6A4SLC6A3CHRNB2CHRNA7
SCHEMBL5845604 0.70 BACE1 (0.39) BACE1SLC6A4SLC6A3KCNH2ADRA1A
SCHEMBL14433407 0.68 BACE1 (0.97) BACE1SLC6A4SLC6A3HSD11B1NR1I2
SCHEMBL8280835 0.67 BACE1 (1.00) BACE1SLC6A4SLC6A3HSD11B1HSD11B2
SCHEMBL5846154 0.67 BACE1 (0.44) BACE1DRD2TSHRSIGMAR1
SCHEMBL8280838 0.65 BACE1 (0.94) BACE1HSD11B1NR1I2HSD11B2
SCHEMBL5845512 0.64 BACE1 (0.54) BACE1HSD11B1NR1I2HSD11B2DCAF15
SCHEMBL5846112 0.63 BACE1 (0.49) BACE1KCNH2HSD11B1NR1I2SIGMAR1
SCHEMBL5844691 0.61 BACE1 (0.47) BACE1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087623-B2 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof SEPRACOR INC. (US) 2006-08-08 US disclosed
US-20040235913-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof CUNY GREGORY D (US) 2004-11-25 US disclosed
US-6699866-B2 FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS SEPRACOR INC. 2004-03-02 US disclosed
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-06-05 US disclosed
WO-2002083863-A2 THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF SEPRACOR, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235913-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof HTR5A, OPRL1, HTR2C BACE1 358/4885SLC6A4 20/4885SLC6A3 17/4885
US-20030105071-A1 Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof HTR5A, OPRL1, HTR2C BACE1 358/4885SLC6A4 20/4885SLC6A3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.